Analysis of Wanjia Group (00401.HK) Being Listed on the Hong Kong Stock Surge List

Wanjia Group (00401.HK) is a company engaged in hemodialysis business under the healthcare/biotechnology sector [5]. On December 10, the stock closed at HK$0.120, up 3.5% from the previous day, with a trading volume of HK$12,000 [5], entering the Hong Kong Stock Surge List on the East Money App due to its increase [1]. Recent price fluctuations are significant: it once fell 9.231% to HK$0.118 on December 8 [4], then rebounded and recovered some losses on December 10.

Financial aspects: The company released its interim report on November 19, showing that for the six months ended September 30, 2025, revenue increased by 2.4% year-on-year, but the loss attributable to shareholders from operating businesses was HK$712,000 [2], turning from a profit of HK$125,600 in the same period last year to a loss. Regulatory aspect: On October 28, the company issued a voluntary announcement stating that its indirectly non-wholly-owned subsidiary, Wuhua Yangke Kidney Dialysis Hemodialysis Co., Ltd., was suspended from its medical insurance service agreement by the local medical insurance management center for 61 days due to prescription management violations; the company said the incident would not have a material adverse impact on the group’s financial position [3].

1. Short-term Rebound May Be Speculative Trading
   : The recent trading volume of the stock is only HK$12,000 [5], indicating low market participation. The increase on December 10 may be a short-term rebound from the decline on December 8, rather than driven by fundamental improvements.
2. Coexistence of Financial and Regulatory Pressures
   : The company has interim losses and slow revenue growth [2], coupled with the medical insurance violation incident of its subsidiary [3]. Although the company claims the impact is limited, there are still uncertainties regarding subsequent regulatory inspections and rectifications.
3. Market Sentiment Dominated by Speculation
   : The stock entered the surge list due to short-term increases, but the weak fundamentals contrast with price fluctuations, indicating that market sentiment is dominated by speculative trading, lacking long-term support.

1. Financial Risk
   : Interim operating losses and weak revenue growth reflect the company’s weak business profitability [2].
2. Regulatory Risk
   : The suspension of the subsidiary’s medical insurance service agreement may lead to further regulatory reviews, posing potential impacts on the company’s operations [3].
3. Liquidity and Speculative Risk
   : Low trading volume leads to insufficient liquidity; short-term price fluctuations may be caused by speculative trading, so investors need to be alert to the risk of chasing highs [4][5].

No significant fundamental opportunities are found currently; attention should be paid to the progress of the company’s business expansion or resolution of regulatory issues.

• Wanjia Group (00401.HK) made it to the Hong Kong Stock Surge List due to short-term price rebound [1].
• As of December 10, closing price was HK$0.120, with an increase of 3.5% and trading volume of HK$12,000 [5].
• Interim report shows slight revenue increase but loss, and suspension of the subsidiary’s medical insurance service agreement [2][3].
• Market sentiment is dominated by speculation, with large price fluctuations; need to be alert to financial, regulatory, and liquidity risks.